Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Christophe Boetsch"'
Autor:
Loic Verlingue, Antoine Italiano, Hans Prenen, Eva Maria Guerra Alia, Diego Tosi, Ruth Perets, Iwona Lugowska, Vladimir Moiseyenko, Mahmut Gumus, Cagatay Arslan, Colin R. Lindsay, Sanjeev Deva, Álvaro Taus, Ana Oaknin, Sylvie Rottey, Irfan Cicin, Sema Sezgin Goksu, Alexey Smolin, Susana Roselló-Keränen, Christin Habigt, Daniel Marbach, Christophe Boetsch, David Dejardin, Nassim Sleiman, Stefan Evers, Muriel Richard, Caroline Ardeshir, Jehad Charo, Anton Kraxner, Volker Teichgräber, Nino Keshelava, Rafal Dziadziuszko
Publikováno v:
EBioMedicine, Vol 109, Iss , Pp 105374- (2024)
Summary: Background: Simlukafusp alfa (FAP-IL2v) is an immune cytokine engineered to selectively promote immune responses in the tumour microenvironment. We evaluated the antitumour activity and safety of FAP-IL2v plus atezolizumab in recurrent and/o
Externí odkaz:
https://doaj.org/article/2eb15235333d4a14935f9abccb626cd2
Autor:
Christian Klein, Marina Bacac, Pablo Umana, Gabrielle Leclercq, Hélène Haegel, Anneliese Schneider, Anna Maria Giusti, Estelle Marrer-Berger, Christophe Boetsch, Antje-Christine Walz, Vesna Pulko, Johannes Sam, John Challier, Cristiano Ferlini, Alex Odermatt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Background T cell engagers are bispecific antibodies recognizing, with one moiety, the CD3ε chain of the T cell receptor and, with the other moiety, specific tumor surface antigens. Crosslinking of CD3 upon simultaneous binding to tumor antigens tri
Externí odkaz:
https://doaj.org/article/d740d1ec08cc48e2a5963b382b89f9bb
Autor:
Volker Teichgräber, Pavel Pisa, Alex Phipps, Jean Eric Charoin, Jean Tessier, Christian Klein, Stefan Evers, Jehad Charo, Hans Peter Grimm, Tapan Nayak, Christophe Boetsch, Benjamin Ribba
Supplemental legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a35ccf90ebb95538b3b96ffdcec280c
https://doi.org/10.1158/1078-0432.22465131.v1
https://doi.org/10.1158/1078-0432.22465131.v1
Autor:
Volker Teichgräber, Pavel Pisa, Alex Phipps, Jean Eric Charoin, Jean Tessier, Christian Klein, Stefan Evers, Jehad Charo, Hans Peter Grimm, Tapan Nayak, Christophe Boetsch, Benjamin Ribba
Supplementary Figure S1: Left: CEA expression by immuno-histochemistry in the LS174T tumor mouse model: homogeneous cytoplasmic antigen distribution. Right: CEA expression in one of the treated patients (colorectal cancer): heterogeneous cytoplasmic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b987aad8cb87c9dc01c6d5be388abbc
https://doi.org/10.1158/1078-0432.22465140
https://doi.org/10.1158/1078-0432.22465140
Autor:
Volker Teichgräber, Pavel Pisa, Alex Phipps, Jean Eric Charoin, Jean Tessier, Christian Klein, Stefan Evers, Jehad Charo, Hans Peter Grimm, Tapan Nayak, Christophe Boetsch, Benjamin Ribba
Purpose: Optimal dosing is critical for immunocytokine-based cancer immunotherapy to maximize efficacy and minimize toxicity. Cergutuzumab amunaleukin (CEA-IL2v) is a novel CEA-targeted immunocytokine. We set out to develop a mathematical model to pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2556a1ba8acaa2fde530ba00d2a6d156
https://doi.org/10.1158/1078-0432.c.6525936
https://doi.org/10.1158/1078-0432.c.6525936
Autor:
Oliver Krieter, Kay Stubenrauch, Kevin Smart, Simona Rossomanno, Tapan Nayak, Anthony Morel, Katharina Lechner, Angelika Lahr, Florian Heil, Izolda Franjkovic, Christophe Boetsch, Andrea Varga, Ratislav Bahleda, Marie Alt, Marie-Paule Sablin, Joan Albanell, Alvaro Taus, Valentina Boni, Elena Garralda, Christophe Massard, Christophe Le Tourneau, Maria Martinez-Garcia, Manuel Hidalgo
Purpose: Vanucizumab is an investigational antiangiogenic, first-in-class, bispecific mAb targeting VEGF-A and angiopoietin-2 (Ang-2). This first-in-human study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of vanuc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b997dc23460b77731f450444acbeccd
https://doi.org/10.1158/1078-0432.c.6525932.v1
https://doi.org/10.1158/1078-0432.c.6525932.v1
Autor:
Oliver Krieter, Kay Stubenrauch, Kevin Smart, Simona Rossomanno, Tapan Nayak, Anthony Morel, Katharina Lechner, Angelika Lahr, Florian Heil, Izolda Franjkovic, Christophe Boetsch, Andrea Varga, Ratislav Bahleda, Marie Alt, Marie-Paule Sablin, Joan Albanell, Alvaro Taus, Valentina Boni, Elena Garralda, Christophe Massard, Christophe Le Tourneau, Maria Martinez-Garcia, Manuel Hidalgo
Supplementary Table S1. Criteria for defining dose-limiting toxicities; Supplementary Table S2. Plasma pharmacokinetic parameters of vanucizumab on Cycles 1 and 4 following bi-weekly administration of ascending doses of vanucizumab; Supplementary Tab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::555574349a2403fbb0a8b72519ed80b7
https://doi.org/10.1158/1078-0432.22465118.v1
https://doi.org/10.1158/1078-0432.22465118.v1
Autor:
Volker Teichgräber, Pavel Pisa, Alex Phipps, Jean Eric Charoin, Jean Tessier, Christian Klein, Stefan Evers, Jehad Charo, Hans Peter Grimm, Tapan Nayak, Christophe Boetsch, Benjamin Ribba
Supplemental Table S2: Model parameter estimates. For model equations, refer to supplemental material.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::546194bedc8c55f6656385f52b67c758
https://doi.org/10.1158/1078-0432.22465122.v1
https://doi.org/10.1158/1078-0432.22465122.v1
Autor:
Tamara Tanos, Kevin Smart, Valentina Gambardella, Kristoffer Rohrberg, Michael Ong, Maria Esperanza Rodriguez Ruiz, Jean-Pascal Machiels, Miguel Fernández Sanmamed, Josep Tabernero, Anna Spreafico, Daniel Renouf, Stephen Luen, Rachel Galot, Bernard Doger, Emiliano Calvo, Aung Naing, Samira Curdt, Nicolas Staedler, Mike Flores, Enrique Gómez Alcaide, Chiahuey Ooi, Michael Hettich, Sebastian Dziadek, Yuying Xie, Gabriel Schnetzler, Theresa Kolben, Linxinyu Xu, Vaios Karanikas, Christophe Boetsch
Publikováno v:
Cancer Research. 83:CT176-CT176
INTRODUCTION: Activated Tregs in the tumor micro-environment are correlated with poor outcomes, and are considered as key players in tumor immune-escape. So far, Treg depletion has not been successful in patients, either because adequate Treg depleti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::217a7c59c9c441d0bb31a8fa513d8cd9
https://doi.org/10.1158/1538-7445.am2023-ct176
https://doi.org/10.1158/1538-7445.am2023-ct176
Autor:
Johannes Sam, Dafne Franz Demane, Estelle Marrer-Berger, Mariana Werner Sunderland, Christophe Boetsch, Dimitrios Zervas, Anne Goubier, Jake Y. Henry, Teresa Marafioti, Chen Qing, Jan Eckmann, Frederick Arce Vargas, Reto Flury, Sara Belli, Hans Koll, Ayse Akarca, Maria Amann, Bjoern Jacobsen, Lea Leibrock, Anna Śledzińska, Roger Sutmuller, Sergio A. Quezada, Josephine Salimu, Joerg Benz, Claudio Murgia, Isabelle Solomon, Joanne Ruth Clancy, Mark Adrian Brown, Karl S. Peggs, Pascal Merchiers, Ehsan Ghorani, Andrew Georgiou
Publikováno v:
Nature Cancer. 1:1153-1166
Intratumoral regulatory T (Treg) cell abundance associates with diminished antitumor immunity and poor prognosis in human cancers. Recent work demonstrates that CD25, the high-affinity receptor subunit for interleukin (IL)-2, is a selective target fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c86e7b1e8eb4c4edbef7ab01a2f5de0
https://doi.org/10.1038/s43018-020-00133-0
https://doi.org/10.1038/s43018-020-00133-0